286 related articles for article (PubMed ID: 35121945)
1. Acquired resistance to anti-MAPK targeted therapy confers an immune-evasive tumor microenvironment and cross-resistance to immunotherapy in melanoma.
Haas L; Elewaut A; Gerard CL; Umkehrer C; Leiendecker L; Pedersen M; Krecioch I; Hoffmann D; Novatchkova M; Kuttke M; Neumann T; da Silva IP; Witthock H; Cuendet MA; Carotta S; Harrington KJ; Zuber J; Scolyer RA; Long GV; Wilmott JS; Michielin O; Vanharanta S; Wiesner T; Obenauf AC
Nat Cancer; 2021 Jul; 2(7):693-708. PubMed ID: 35121945
[TBL] [Abstract][Full Text] [Related]
2. Mechanisms of Drug Resistance in Melanoma.
Winder M; Virós A
Handb Exp Pharmacol; 2018; 249():91-108. PubMed ID: 28275910
[TBL] [Abstract][Full Text] [Related]
3. The immune microenvironment confers resistance to MAPK pathway inhibitors through macrophage-derived TNFα.
Smith MP; Sanchez-Laorden B; O'Brien K; Brunton H; Ferguson J; Young H; Dhomen N; Flaherty KT; Frederick DT; Cooper ZA; Wargo JA; Marais R; Wellbrock C
Cancer Discov; 2014 Oct; 4(10):1214-1229. PubMed ID: 25256614
[TBL] [Abstract][Full Text] [Related]
4. Future perspectives in melanoma research: meeting report from the "Melanoma Bridge": Napoli, December 3rd-6th 2014.
Ascierto PA; Atkins M; Bifulco C; Botti G; Cochran A; Davies M; Demaria S; Dummer R; Ferrone S; Formenti S; Gajewski TF; Garbe C; Khleif S; Kiessling R; Lo R; Lorigan P; Arthur GM; Masucci G; Melero I; Mihm M; Palmieri G; Parmiani G; Puzanov I; Romero P; Schilling B; Seliger B; Stroncek D; Taube J; Tomei S; Zarour HM; Testori A; Wang E; Galon J; Ciliberto G; Mozzillo N; Marincola FM; Thurin M
J Transl Med; 2015 Nov; 13():374. PubMed ID: 26619946
[TBL] [Abstract][Full Text] [Related]
5. Future perspectives in melanoma research : Meeting report from the "Melanoma Bridge". Napoli, December 1st-4th 2015.
Ascierto PA; Agarwala S; Botti G; Cesano A; Ciliberto G; Davies MA; Demaria S; Dummer R; Eggermont AM; Ferrone S; Fu YX; Gajewski TF; Garbe C; Huber V; Khleif S; Krauthammer M; Lo RS; Masucci G; Palmieri G; Postow M; Puzanov I; Silk A; Spranger S; Stroncek DF; Tarhini A; Taube JM; Testori A; Wang E; Wargo JA; Yee C; Zarour H; Zitvogel L; Fox BA; Mozzillo N; Marincola FM; Thurin M
J Transl Med; 2016 Nov; 14(1):313. PubMed ID: 27846884
[TBL] [Abstract][Full Text] [Related]
6. Immunotolerance as a Mechanism of Resistance to Targeted Therapies in Melanoma.
Mandalà M; Massi D
Handb Exp Pharmacol; 2018; 249():129-143. PubMed ID: 28238077
[TBL] [Abstract][Full Text] [Related]
7. Immunomodulatory effects of BRAF and MEK inhibitors: Implications for Melanoma therapy.
Kuske M; Westphal D; Wehner R; Schmitz M; Beissert S; Praetorius C; Meier F
Pharmacol Res; 2018 Oct; 136():151-159. PubMed ID: 30145328
[TBL] [Abstract][Full Text] [Related]
8. TIGIT/CD155 axis mediates resistance to immunotherapy in patients with melanoma with the inflamed tumor microenvironment.
Kawashima S; Inozume T; Kawazu M; Ueno T; Nagasaki J; Tanji E; Honobe A; Ohnuma T; Kawamura T; Umeda Y; Nakamura Y; Kawasaki T; Kiniwa Y; Yamasaki O; Fukushima S; Ikehara Y; Mano H; Suzuki Y; Nishikawa H; Matsue H; Togashi Y
J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34795004
[TBL] [Abstract][Full Text] [Related]
9. ZEB1 transcription factor promotes immune escape in melanoma.
Plaschka M; Benboubker V; Grimont M; Berthet J; Tonon L; Lopez J; Le-Bouar M; Balme B; Tondeur G; de la Fouchardière A; Larue L; Puisieux A; Grinberg-Bleyer Y; Bendriss-Vermare N; Dubois B; Caux C; Dalle S; Caramel J
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35288462
[TBL] [Abstract][Full Text] [Related]
10. Immune Responses to BRAF-Targeted Therapy in Melanoma: Is Targeted Therapy Immunotherapy?
Kelley MC
Crit Rev Oncog; 2016; 21(1-2):83-91. PubMed ID: 27481005
[TBL] [Abstract][Full Text] [Related]
11. Tumor microenvironment changes leading to resistance of immune checkpoint inhibitors in metastatic melanoma and strategies to overcome resistance.
Pulluri B; Kumar A; Shaheen M; Jeter J; Sundararajan S
Pharmacol Res; 2017 Sep; 123():95-102. PubMed ID: 28690075
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of endothelin-B receptor signaling synergizes with MAPK pathway inhibitors in BRAF mutated melanoma.
Schäfer A; Haenig B; Erupathil J; Strickner P; Sabato D; Welford RWD; Klaeylé L; Simon E; Krepler C; Brafford P; Xiao M; Herlyn M; Gstaiger M; Lehembre F; Renz I
Oncogene; 2021 Mar; 40(9):1659-1673. PubMed ID: 33500549
[TBL] [Abstract][Full Text] [Related]
13. A Feed-Forward Mechanosignaling Loop Confers Resistance to Therapies Targeting the MAPK Pathway in BRAF-Mutant Melanoma.
Girard CA; Lecacheur M; Ben Jouira R; Berestjuk I; Diazzi S; Prod'homme V; Mallavialle A; Larbret F; Gesson M; Schaub S; Pisano S; Audebert S; Mari B; Gaggioli C; Leucci E; Marine JC; Deckert M; Tartare-Deckert S
Cancer Res; 2020 May; 80(10):1927-1941. PubMed ID: 32179513
[TBL] [Abstract][Full Text] [Related]
14. Myeloid Cells That Impair Immunotherapy Are Restored in Melanomas with Acquired Resistance to BRAF Inhibitors.
Steinberg SM; Shabaneh TB; Zhang P; Martyanov V; Li Z; Malik BT; Wood TA; Boni A; Molodtsov A; Angeles CV; Curiel TJ; Whitfield ML; Turk MJ
Cancer Res; 2017 Apr; 77(7):1599-1610. PubMed ID: 28202513
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of p90 ribosomal S6 kinases disrupts melanoma cell growth and immune evasion.
Kosnopfel C; Wendlinger S; Niessner H; Siewert J; Sinnberg T; Hofmann A; Wohlfarth J; Schrama D; Berthold M; Siedel C; Sauer B; Jayanthan A; Lenz G; Dunn SE; Schilling B; Schittek B
J Exp Clin Cancer Res; 2023 Jul; 42(1):175. PubMed ID: 37464364
[TBL] [Abstract][Full Text] [Related]
16. Gut Microbiota and Therapy in Metastatic Melanoma: Focus on MAPK Pathway Inhibition.
Guardamagna M; Berciano-Guerrero MA; Villaescusa-González B; Perez-Ruiz E; Oliver J; Lavado-Valenzuela R; Rueda-Dominguez A; Barragán I; Queipo-Ortuño MI
Int J Mol Sci; 2022 Oct; 23(19):. PubMed ID: 36233289
[TBL] [Abstract][Full Text] [Related]
17. Epigenetic control of
Wang MM; Koskela SA; Mehmood A; Langguth M; Maranou E; Figueiredo CR
Front Immunol; 2023; 14():1152228. PubMed ID: 37077920
[TBL] [Abstract][Full Text] [Related]
18. Transient cell-in-cell formation underlies tumor relapse and resistance to immunotherapy.
Gutwillig A; Santana-Magal N; Farhat-Younis L; Rasoulouniriana D; Madi A; Luxenburg C; Cohen J; Padmanabhan K; Shomron N; Shapira G; Gleiberman A; Parikh R; Levy C; Feinmesser M; Hershkovitz D; Zemser-Werner V; Zlotnik O; Kroon S; Hardt WD; Debets R; Reticker-Flynn NE; Rider P; Carmi Y
Elife; 2022 Sep; 11():. PubMed ID: 36124553
[TBL] [Abstract][Full Text] [Related]
19. The future of targeted kinase inhibitors in melanoma.
Caksa S; Baqai U; Aplin AE
Pharmacol Ther; 2022 Nov; 239():108200. PubMed ID: 35513054
[TBL] [Abstract][Full Text] [Related]
20. Mutant BRAF and MEK Inhibitors Regulate the Tumor Immune Microenvironment via Pyroptosis.
Erkes DA; Cai W; Sanchez IM; Purwin TJ; Rogers C; Field CO; Berger AC; Hartsough EJ; Rodeck U; Alnemri ES; Aplin AE
Cancer Discov; 2020 Feb; 10(2):254-269. PubMed ID: 31796433
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]